Working With Healthcare Professionals | Lupin Healthcare Limited

The Department of Health and Social Care (DHSC) defines joint working between the NHS and the pharmaceutical industry as situations where, for the benefit of patients, one or more pharmaceutical companies and the NHS pool skills, experience and/or resources for the joint development and implementation to improve patient care for successful delivery.

Lupin are fully committed to partnering with the NHS to develop new services and pathways that better serve the needs of patients.

Lupin proudly supports healthcare organisations and patient organisations with medical and educational activities to enhance and maintain patient care and benefit research, which are termed grants.

Requests for grants/donations must be for a specific activity or event. It must be submitted independently of Lupin, and there can be no benefit to Lupin as a result.

To submit a grant/donation request please send to UKMedical@lupin.com.

To submit for a sponsorship request to conference or an educational meeting/course, please send to UKMedical@lupin.com

We value the work of patient groups and the important role they play in supporting patients whose lives are affected by various medical conditions/illnesses.

Lupin works with and supports patient organisations in order to understand the patient’s views of their condition. Providing accurate, useful information for the public and patients to improve patient outcomes and/or patient experience with the care they receive.

Lupin ensures it acts with a high degree of integrity and transparency. As a member of The Association of the British Pharmaceutical Industry (ABPI), we must declare a list of patient organisations to which we provide financial support and/or significant non-financial support.

To ensure transparency of our partnerships with patient groups, we declare all funding which we provide. A full list of funding in 2020 will be published in June 2021.

Lupin is passionate about advancing health and addressing the unmet needs of patients. To do this, we must closely enagage with healthcare organisations (HCOs) and Healthcare professionals (HCPs) for scientific expertise.

We provide payments and funding to HCPs for their time and expertise. We also provide funding to HCOs to support patient care or to benefit the NHS, and to organisations for research and development (R&D).

The pharmaceutical industry is committed to greater transparency of financial relationships with HCPs and HCOs.

We adhere to the Association of the British Pharmaceutical Industry (ABPI) code and will disclose payments and benefits to HCPs and HCOs. Lupin discloses details of certain Transfer of Value (ToV) payments and benefits to individually named HCPs and HCOs on a publicly searchable database, Disclosure UK, which is hosted on the ABPI website.

Full disclosure of value for 2020 will be published in June 2021.

For more Information about studies for a Lupin medicine, both worldwide and in the UK, please visit independent registries such as https://www.clinicaltrials.gov/ and https://eudract.ema.europa.eu/.

The UK Clinical Trials Gateway (UKCTG) also provides a comprehensive list of clinical research studies running in the UK.

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the leaflet. You can also report side effects directly by the Yellow Card Scheme website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

Contact us